ENTYVIO / KYNTELES Takeda Pharmaceuticals Australia Pty Ltd
Product name
ENTYVIO / KYNTELES
Accepted date
Nov-2022
Active ingredients
vedolizumab
Proposed indication
For the treatment of Pouchitis.
Application type
C (new medicine)
Publication date
Nov-22
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.